Uncategorized-EN
Tebentafusp in HLA-A*02:01 Positive Patients with advanced Clear Cell Sarcoma
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma Agent: Tebentafusp vs. Physician’s choice Phase II Status Recruiting Sponsor Sarcoma Alliance for Research through Collaboration (SARC) For further information please also consult https://clinicaltrials.gov/study/NCT06942442 This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell…
Read MoreStrateGIST 3
StrateGIST 3: IDRX-42 vs. Sunitinib in patients with metastatic or unresectable GIST, after first-line Imatinib treatment. Agent: IDRX-42 Sunitinib Phase III Status Recruiting Sponsor GlaxoSmithKline For further information please consult https://clinicaltrials.gov/study/NCT07218926 The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating…
Read MoreMaking Expert Knowledge Accessible: New Lay Summary of Desmoid Tumor Consensus
SPAGN has released a new lay summary of the international expert consensus on the management of desmoid tumors, originally published in JAMA Oncology in 2024. While the scientific article was written for clinicians and researchers, the new summary translates its key messages into clear, accessible language for patients, families, and advocates. Highly technical medical publications…
Read MoreShare Your Experience: Contribute to the CURE ID Sarcoma
Patients, care partners, and healthcare providers are invited to share their experiences through the Sarcoma Treatment Survey on CURE ID. CURE ID is a free website and mobile app developed by the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) in collaboration with several patient and clinical organizations. The platform…
Read MoreGD2-SADA: 177Lu-DOTA
GD2-SADA: 177Lu-DOTA in GD2-Positive Tumors Agent: GD2-SADA, 177Lu-DOTA Phase I Status Recruiting Sponsor Y-mAbs Therapeutics For further information please also consult https://clinicaltrials.gov/study/NCT05130255 Patients with Sarcoma, Small Cell Lung Cancer, High Risk Neuroblastoma, or Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex. The treatment uses a two-step approach (pre-targeted radioimmunotherapy). GD2-SADA – a specially designed…
Read MoreATLAS
Actinium Therapy for Late-stage Aggressive Sarcomas (ATLAS) Agent: [Ac-225] RTX-2358, Diagnostic test: [Cu64]LNTH-1363S Phase I/II Status Recruiting Sponsor Ratio Therapeutics, Inc. For further information please also consult https://www.clinicaltrials.gov/study/NCT07071727 This is a first-in-human, Phase 1/2, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, dosimetry, biodistribution, pharmacokinetics, and preliminary anti-tumor activity of [Ac-225] RTX-2358…
Read MoreWhen standard care is not enough: Swedish hospital runs Whole Genome Sequencing routinely for sarcoma
Ahead of this year’s Annual Conference of SPAGN in Stockholm from 1- 3 May, the Swedish patient advocate Magnus Carlsson shares exciting developments in his country regarding genomic profiling of tumours suspicious of sarcoma. He explains why he believes that running Whole Genomic Sequencing routinely in the diagnostic process is an investment rather than an expense.
Read MoreUSA: The Ewing Sarcoma Institute
USA: The Ewing Sarcoma Institute Back to members Organization profile: The mission of the Ewing Sarcoma Institute: The Ewing Sarcoma Institute is dedicated to radically improving outcomes for Ewing Sarcoma patients by uniting the global community to accelerate collaborative scientific discovery and development of breakthrough treatments. Contact Information The Ewing Sarcoma Institute 5433 La Sierra…
Read MoreWECAN Patient Experience Data (PED) online course launching on World Cancer Day
Are you part of a patient organisation that wants to shape healthcare decisions, but doesn’t always know where to start? On 4 February, WECAN Foundation will launch a free online course on Patient Experience Data (PED) for patients, advocates, patient leaders but also people interested in generating PED within the cancer advocacy work. This launch comes at a time when patient experience and quality of life are receiving…
Read MoreROGER EXPLORES… Ultrasound
In the panoply of new technologies for treating cancer ultra-sound barely gets a mention. In this blog post Roger Wilson discovers how it is developing as a treatment. He explains why he believes this a worthwhile process to observe.
Read More